Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth

• The Hurun Research Institute recently released the Hurun Future Unicorns in the World 2023, and Chime Biologics was relisted among the Global Gazelle.

Wuhan, China, August 17, 2023 – The Hurun Research Institute recently released the Hurun Future Unicorns in the World 2023, a list of the world’s Gazelles. Chime Biologics, a leading CDMO headquartered in Wuhan, China, has been listed again.

Third time Selected as Gazelle Enterprise

Chime Biologics stands out among numerous biopharmaceutical enterprises and ranks on the list. This is the 3^rd  time Chime Biologics has been selected as a “Gazelle Enterprise” since 2021. As a continuously selected world’s gazelle enterprise, it demonstrates the growth and has received long-term recognition from worldwide market.

In 2021, Hurun Research Institute first released the Global Gazelle Enterprises list, when for the first time Chime Biologics was selected. In August 2022, it released the Hurun Global Gazelle Index 2022 Half Year Report, and Chime Biologics was selected again.

Standing Out in the Biotech Industry Globally

Gazelle enterprise is defined as start-ups founded in the 2000s, worth over US$500mn, not yet listed on a public exchange and most likely to ‘go unicorn’, ie hit a valuation of US$1bn, within three years. The Hurun Future Unicorns series is made up of Gazelles, this list here, most likely to ‘go unicorn’ within three years, and Cheetahs, most likely to ‘go unicorn’ within five years. The cut-off date used was 31 December 2022. This is the third edition of the list. (source: https://www.hurun.net)

This time, Hurun Research Institute found a total of 688 gazelle enterprises globally, with 13% of the biotech industry. As a gazelle enterprise, Chime Biologics will continually adhere to ingenuity, make unceasing progress. Making cutting-edge biologics affordable and accessible to all patients globally, fulfilling its commitment to human health.

About Chime Biologics

Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health.  For more information, please visit www.chimebiologics.com.